This study, involving eight healthy volunteers, revealed that food intake does not have a clinically significant effect on vigabatrin kinetics. 2. Kinetics of vigabatrin in the fasting state showed low inter-individual variation. 3. The plasma concentration vs time profile followed a bi-exponential decline with a terminal half-life of 6.8 h and a relative bioavailability of 92% +/- 11%. 4. In the clinical setting, vigabatrin may be taken at times convenient for the patient.
No takes yet. Share an insight, caveat, or question.
Frisk‐Holmberg et al. (1989) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: